Cantor Fitzgerald Comments on Gossamer Bio FY2025 Earnings

Gossamer Bio, Inc. (NASDAQ:GOSS) – Investment analysts at Cantor Fitzgerald boosted their FY2025 EPS estimates for shares of Gossamer Bio in a research report issued to clients and investors on Monday, March 24th. Cantor Fitzgerald analyst O. Brayer now anticipates that the company will post earnings of ($0.70) per share for the year, up from their prior forecast of ($0.72). The consensus estimate for Gossamer Bio’s current full-year earnings is ($0.28) per share.

Other equities analysts have also issued reports about the stock. Wedbush reissued an “outperform” rating and set a $4.00 price target on shares of Gossamer Bio in a research report on Friday, March 14th. HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Gossamer Bio in a report on Tuesday, March 18th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Gossamer Bio has an average rating of “Buy” and an average target price of $9.20.

Gossamer Bio Trading Down 7.8 %

Gossamer Bio stock opened at $1.18 on Wednesday. The stock has a 50-day moving average price of $1.19 and a 200 day moving average price of $0.99. The company has a market capitalization of $268.12 million, a price-to-earnings ratio of -3.69 and a beta of 1.86. Gossamer Bio has a 52 week low of $0.50 and a 52 week high of $1.55. The company has a quick ratio of 6.74, a current ratio of 6.74 and a debt-to-equity ratio of 3.64.

Gossamer Bio (NASDAQ:GOSS) last posted its quarterly earnings data on Tuesday, March 18th. The company reported ($0.15) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.15). The company had revenue of $9.38 million for the quarter, compared to analyst estimates of $7.02 million.

Institutional Investors Weigh In On Gossamer Bio

Institutional investors have recently modified their holdings of the company. GSA Capital Partners LLP purchased a new stake in Gossamer Bio during the third quarter worth about $67,000. The Manufacturers Life Insurance Company increased its stake in Gossamer Bio by 24.2% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 385,133 shares of the company’s stock worth $380,000 after buying an additional 74,920 shares during the period. Monaco Asset Management SAM increased its stake in Gossamer Bio by 39.5% during the 4th quarter. Monaco Asset Management SAM now owns 5,371,641 shares of the company’s stock worth $4,859,000 after buying an additional 1,520,721 shares during the period. Jacobs Levy Equity Management Inc. lifted its holdings in Gossamer Bio by 30.7% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 1,887,512 shares of the company’s stock worth $1,862,000 after buying an additional 442,895 shares in the last quarter. Finally, Octagon Capital Advisors LP boosted its position in Gossamer Bio by 99.7% in the 4th quarter. Octagon Capital Advisors LP now owns 18,350,000 shares of the company’s stock valued at $16,599,000 after buying an additional 9,162,117 shares during the period. 81.23% of the stock is owned by institutional investors and hedge funds.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.